2D and 3D Cellular Screening Models and AI Guided Analysis, Volume 204 explores the development, application, and comparative benefits of 2D monolayer cultures and 3D organoids, spheroids, and tissue-engineered constructs for biomedical research and drug discovery. Chapters in this new release include High throughput CellTiter-glo viability assessment, Assessing viability of cancer cell spheroids in 3D drug screening, 3D killing assay of cancer spheroids by cytotoxic T lymphocytes in anchored microfluidic droplets, Use of micropatterning for 3D cell culture, Use of microfluidic chip devices for assessing the effect of radiation on 3D cell culture models, and much more.
Additional chapters cover A 3D model for assessing regulated cell death modalities, YOLO detection model for Cell Viability assessment, Bioinformatics and AI/ML approaches using multi-omics data to accelerate diagnosis and delivery of precision care, Automated image analysis and machine learning for the assessment of mitochondrial membrane potential, Assessing cancer cell heterogeneity in patient-derived tumoroids, Assessment of lysosomal drug sequestration and release using fluorescence microscopy, Assessment of T cell toxicity in ex-vivo models of cancer, Three-dimensional Organoid Screening using Leica Thunder Microscope, Using vascularized organoids-on-chip for assessing systemic drug delivery, and many more interesting and timely topics.
- Includes detailed methodologies and protocols for developing both 2D monolayer and 3D spheroid/organoid cellular screening models
- Presents in-depth comparisons of the advantages, limitations, and applications of 2D vs. 3D cellular models in research and drug discovery
- Provides high-throughput and high-content screening methods for assessing cellular responses
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Dr. Oliver Kepp graduated from Humboldt University Berlin and obtained a PhD degree in Molecular Biology. Today he is a tenured researcher at INSERM and a Co-director of the BioCell automation platform at GRCC. Oliver and his team investigate several aspects of tumor immunogenicity, focusing on systems cell biology approaches. He is also a co-founder of Samsara therapeutics and was appointed associate director of the European academy of tumor immunology in 2019. Oliver received the prestigious Clarivate Highly Cited Researcher Award four years in a row since 2018 and has recently been ranked among the top biology and biochemistry scientists in France (#5; www.research.com)
Guido Kroemer got his M.D. in 1985 from the University of Innsbruck, Austria, and his Ph.D. in molecular biology in 1992 from the Autonomous University of Madrid, Spain. He is currently Professor at the Faculty of Medicine of the University of Paris Descartes/Paris V, Director of the INSERM research team ‘Apoptosis, Cancer and Immunity’, Director of the Metabolomics and Cell Biology platforms of the Gustave Roussy Cancer Campus, and Practitioner at the Hôpital Européen George Pompidou (Paris, France). He is also the Director of the Paris Alliance of Cancer Research Institutes (PACRI) and the Labex 'Immuno-Oncology'. Dr. Kroemer is best known for the discoveries that mitochondrial membrane permeabilization constitutes a decisive step in regulated cell death; that autophagy is a cytoprotective mechanism with lifespan-extending effects; and that anticancer therapies are successful only if they stimulate tumour-targeting immune responses. He is currently the most-cited cell biologist in Europe (relative to the period 2007-2013), and he has received the Descartes Prize of the European Union, the Carus Medal of the Leopoldina, the Dautrebande Prize of the Belgian Royal Academy of Medicine, the Léopold Griffuel Prize of the French Association for Cancer Research, the Mitjavile prize of the French National Academy of Medicine and a European Research Council Advanced Investigator Award.
